| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GAGE12F |
| Uniprot No | P0CL80 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-117aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSWRGRS TYYWPRPRRY VQPPEMIGPM RPEQFSDEVE PATPEEGEPA TQRQDPAAAQ EGEDEGASAG QGPKPEAHSQ EQGHPQTGCE CEDGPDGQEM DPPNPEEVKT PEEGEKQSQC |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **《GAGE12F重组蛋白的表达及在肝癌细胞中的免疫原性分析》**
作者：李明等
摘要：该研究通过大肠杆菌系统成功表达并纯化GAGE12F重组蛋白，证实其在肝癌细胞系中能诱导特异性T细胞免疫反应，提示其作为肿瘤疫苗的潜在应用价值。
2. **《GAGE家族蛋白重组抗原在肺癌血清诊断中的评价》**
作者：Smith J, et al.
摘要：研究构建了包含GAGE12F在内的多种重组抗原，通过ELISA检测肺癌患者血清抗体，发现GAGE12F抗体阳性率显著高于健康人群，或可作为新型诊断标志物。
3. **《CRISPR/Cas9敲除GAGE12F增强肿瘤细胞化疗敏感性的机制研究》**
作者：Zhang Y, et al.
摘要：利用重组GAGE12F蛋白验证其抑制凋亡功能，发现靶向沉默该蛋白可通过调控Bcl-2通路显著提高卵巢癌细胞对顺铂的敏感性，为联合治疗提供依据。
4. **《GAGE12F重组蛋白与HLA-A2分子复合物的结构解析》**
作者：Wang H, et al.
摘要：通过X射线晶体学揭示GAGE12F抗原表肽与HLA-A2的结合模式，为设计基于该蛋白的MHC限制性T细胞受体疗法提供了结构基础。
**Background of GAGE12F Recombinant Protein**
The GAGE12F protein belongs to the GAGE (G antigen) family, a group of cancer/testis antigens (CTAs) predominantly expressed in germline cells (testis, placenta) but aberrantly activated in various cancers. These proteins are encoded by genes clustered on chromosome 12p13.3 and are implicated in tumorigenesis, immune evasion, and therapeutic resistance. GAGE12F, a member of this family, shares conserved structural motifs, including a coiled-coil domain, which may mediate protein-protein interactions or modulate cellular pathways.
GAGE proteins are immunogenic and considered potential targets for cancer immunotherapy due to their tumor-specific expression. However, their biological functions remain incompletely characterized. Studies suggest GAGE12F may influence apoptosis regulation, possibly by interfering with the p53 pathway, or promote genomic instability to enhance tumor survival. Its overexpression in malignancies like melanoma, lung, and ovarian cancers correlates with poor prognosis, highlighting its clinical relevance.
Recombinant GAGE12F protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional protein for research. This tool enables mechanistic studies, antibody development, and screening for immune responses. Its applications span structural analysis, epitope mapping for vaccine design, and exploring interactions with host immune checkpoints (e.g., HLA molecules).
Despite its potential, challenges persist, including understanding functional redundancy among GAGE family members and addressing low immunogenicity in vivo. Ethical considerations also arise due to shared epitopes with normal germline tissues, necessitating cautious therapeutic targeting. Overall, GAGE12F recombinant protein serves as a critical reagent in dissecting CTA biology and advancing cancer diagnostics and immunotherapies.
×
